Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan. Over time, Recordati has expanded its presence through strategic acquisitions and partnerships, enhancing its capabilities in both specialty and haute‐proximal care. Key milestones include the development of one of Europe’s earliest orphan drug programs and the establishment of a dedicated rare diseases division in the early 2000s, which today accounts for a significant portion of its research pipeline.
Recordati conducts research and development activities at its Italian and French facilities, supported by manufacturing sites in Europe. Its international network extends across more than 50 countries, with commercial operations in Europe, North America, Latin America, North Africa and the Middle East. In the United States, Recordati Rare Diseases Inc. focuses on identifying and advancing therapies for underserved patient populations, while its European affiliates manage a broad portfolio of prescription products in primary and specialty care.
Governed by a board of directors that includes members of the founding family alongside independent executives, Recordati maintains a commitment to scientific innovation and patient‐centred solutions. The company collaborates with academic institutions and biotechnology partners to fuel its pipeline of novel therapies, aiming to address unmet medical needs and enhance the quality of life for patients worldwide.
